Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 1997

View Archived Issues

Enzon: fiscal 1997 highlights

Algene: Q2 1997 highlights

Safety profile of VRCTC-310 established in rabbits

Boston Life Sciences reports phase III results for Therafectin

Favorable phase II/III data for Targretin in CTCL reported at dermatology congress

Cytel reports encouraging results from Cylexin phase I/II trial

Dyax issued U.S. patent for novel elastase inhibitors

Genetronics receives NCI grant for electroporation research

Quinacrine sterilization reviewed

Efficacy of Viramune triple drug combination reported at ICAAC

Byk Gulden presents new gastric antisecretory agents

Schering AG prepares new rolipram derivatives

Focus on benzoyl guanidines as Na+/H+-exchange inhibitors

Optically active analgesic agent presented by Roche

New polyene antifungal antibiotic developed at Ajinomoto

BioChem Therapeutic discovers new anti-HCMV agents

Development of YM-46303 stopped

North American Vaccine advances with meningitis B vaccine

Dexketoprofen trometamol submitted for mutual EC recognition

Phase II results reported for Neurobloc

Nyotran study results described at ICAAC

Wakunaga develops new oral fluoroquinolones

T-3811: a new des-F(6)-quinolone from Toyama presented at ICAAC

SynPhar selects class C beta-lactamase inhibitor as development candidate

Cor Therapeutics submits NDA amendment for Integrilin to FDA

First registration filing for Unigene's injectable calcitonin product

Five efavirenz studies reported at ICAAC

Triazole antifungal from Uriach heading for clinic

Fortovase compares favorably with Crixivan and Invirase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...